Healthcare Industry News:  CyDex Pharmaceuticals 


 News Release - November 20, 2007

CyDex Announces New Corporate Name

Changes Name to "CyDex Pharmaceuticals, Inc." to Reflect Current Focus on Acute Care Hospital Products

LENEXA, Kan.--(HSMN NewsFeed)--CyDex, Inc. announced today that it has changed its name to “CyDex Pharmaceuticals, Inc.” CyDex changed its name to reflect its current focus on developing and commercializing its pharmaceutical product candidates. Historically, CyDex’s focus had been on the licensing of its CAPTISOL® technology to pharmaceutical companies.

Future steps in this change of identity will include enhancements to the corporate website (now

“We determined to change our name to reflect the current focus of our company,” said John M. Siebert, Ph.D., Chief Executive Officer of CyDex Pharmaceuticals. “The goal is to create an identity that captures the new CyDex, and to maintain a cohesive and professional image in all of our communications.”

About CyDex Pharmaceuticals

CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its CAPTISOL® enabling technology. CyDex is developing its own pipeline of products using its enabling technology solutions, and partnering with leading pharmaceutical, specialty pharmaceutical and biotechnology companies. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit

CAPTISOL® and Captisol-Enabled® are registered trademarks of CyDex Pharmaceuticals, Inc.

Source: CyDex Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.